Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

[1]  A. Migliaccio,et al.  P‐Selectin Sustains Extramedullary Hematopoiesis in the Gata1low Model of Myelofibrosis , 2016, Stem cells.

[2]  A. Ruggeri,et al.  A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis. , 2015, American journal of blood research.

[3]  M. von Lindern,et al.  CD14+ cells from peripheral blood positively regulate hematopoietic stem and progenitor cell survival resulting in increased erythroid yield , 2015, Haematologica.

[4]  G. Barosi,et al.  Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis. , 2015, Blood cells, molecules & diseases.

[5]  Hu Li,et al.  PPARα and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal , 2015, Nature.

[6]  M. Marconi,et al.  Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype , 2014, Transfusion.

[7]  D. Papatsenko,et al.  Divisional History and Hematopoietic Stem Cell Function during Homeostasis , 2014, Stem cell reports.

[8]  J. Godbold,et al.  Anti-transforming growth factor-β therapy in patients with myelofibrosis , 2014, Leukemia & lymphoma.

[9]  H. Dietz,et al.  Integrin Modulating Therapies Prevent Fibrosis and Autoimmunity in Genetic Mouse Models of Scleroderma , 2013, Nature.

[10]  E. Petricoin,et al.  Transcriptomic and phospho‐proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera , 2013, American journal of hematology.

[11]  K. Matsuzaki.  Smad phospho-isoforms direct context-dependent TGF-β signaling. , 2013, Cytokine & growth factor reviews.

[12]  R. Kalluri,et al.  Origin and function of myofibroblasts in kidney fibrosis , 2013, Nature Medicine.

[13]  G. Barosi,et al.  Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis. , 2013, Blood.

[14]  S. Rafii,et al.  TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy , 2013, The Journal of experimental medicine.

[15]  J. Tripodi,et al.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. , 2012, The Journal of clinical investigation.

[16]  A. Migliaccio,et al.  The expression of the glucocorticoid receptor in human erythroblasts is uniquely regulated by KIT ligand: implications for stress erythropoiesis. , 2012, Stem cells and development.

[17]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[18]  Oliver Distler,et al.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.

[19]  A. Migliaccio,et al.  Under HEMA conditions, self-replication of human erythroblasts is limited by autophagic death. , 2011, Blood cells, molecules & diseases.

[20]  J. Godbold,et al.  The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. , 2011, Blood.

[21]  A. Migliaccio,et al.  Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation. , 2009, Blood.

[22]  M. Le Bousse-Kerdilès,et al.  A Cross‐Talk Between Stromal Cell‐Derived Factor‐1 and Transforming Growth Factor‐β Controls the Quiescence/Cycling Switch of CD34+ Progenitors Through FoxO3 and Mammalian Target of Rapamycin , 2008, Stem cells.

[23]  N. Mahmud,et al.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. , 2007, Blood.

[24]  H. Anderson,et al.  Expression of Bone Morphogenetic Proteins and their Receptors in the Bone Marrow Megakaryocytes of GATA-1low Mice , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  Robert A. Weinberg,et al.  Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type , 2006, Cell cycle.

[26]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[27]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[28]  P. Guglielmelli,et al.  Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. , 2005, The American journal of pathology.

[29]  A. Pancrazzi,et al.  A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. , 2005, Blood.

[30]  Dong-Uk Kim,et al.  Tsc-22 enhances TGF-β signaling by associating with Smad4 and induces erythroid cell differentiation , 2005, Molecular and Cellular Biochemistry.

[31]  A. Migliaccio,et al.  Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. , 2004, Blood.

[32]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[33]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[34]  W. Vainchenker,et al.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.

[35]  A. Migliaccio,et al.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). , 2002, Blood.

[36]  F. Wendling,et al.  Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.

[37]  O. Hermine,et al.  Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. , 2000, Experimental hematology.

[38]  D. J. Van Den Berg,et al.  The Smad5 Gene Is Involved in the Intracellular Signaling Pathways That Mediate the Inhibitory Effects of Transforming Growth Factor-β on Human Hematopoiesis , 1998 .

[39]  T. Stokke,et al.  Transforming growth factor-beta potently inhibits the viability- promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells , 1995 .

[40]  M. Bissell,et al.  The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. , 1995, The Journal of clinical investigation.

[41]  R. Weinberg,et al.  Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Peschle,et al.  Identification and characterization of three classes of erythroid progenitors in human fetal liver. , 1981, Blood.

[43]  A. Balduini,et al.  Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis. , 2011, Cytokine.

[44]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[45]  M. Perricaudet,et al.  Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. , 2007, Experimental hematology.